Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.

Tew, G W; Rabbee, N; Wolslegel, K; Hsieh, H-J; Monroe, J G; Behrens, T W; Brunetta, P G; Keir, M E

Tew, G W; Rabbee, N; Wolslegel, K; Hsieh, H-J; Monroe, J G; Behrens, T W; Brunetta, P G; Keir, M E.

Affiliation

Tew GW; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990, USA.

Lupus ; 19(2): 146-57, 2010 Feb.

Article in En | MEDLINE | ID: mdl-19946034

Subject(s)

Antibodies, Monoclonal/therapeutic use; Autoantibodies/immunology; Immunologic Factors/therapeutic use; Lupus Erythematosus, Systemic/drug therapy; Antibodies, Anticardiolipin/immunology; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal, Murine-Derived; Biomarkers/metabolism; Complement System Proteins/metabolism; DNA/immunology; Double-Blind Method; Follow-Up Studies; Humans; Immunologic Factors/pharmacology; Lupus Erythematosus, Systemic/immunology; RNA-Binding Proteins/immunology; Randomized Controlled Trials as Topic; Rituximab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Immunologic Factors / Lupus Erythematosus, Systemic / Antibodies, Monoclonal Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lupus Journal subject: REUMATOLOGIA Year: 2010 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google